Danish dermatology specialist Leo Pharma is paying $50 million for U.S. gene writing biotech Replay and its preclinical gene therapy for a rare skin disease. Replay launched in 2022 with $55 million ...
New biotech Replay—led by former Pfizer and Bristol Myers Squibb executive Adrian Woolfson, Ph.D.—has unveiled with a $55 million seed financing to reprogram biology and author next generation genomic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results